 NEW YORK, April 12, 2021 PRNewswire -- Today, Hoth Therapeutics, Inc. NASDAQ: HOTH, a patient-focused biopharmaceutical company, together with its manufacturing partner, has successfully completed the formulation for HT-001, a treatment for cancer patients suffering from cutaneous toxicities skin, nails, scalp due to EGFR inhibitor therapies. HT-001 is expected to start its Phase 2a trial in pending approval of the IND submission. 